 |
Ezogabine Dosage
This dosage information may not include all the information needed to use Ezogabine safely and effectively. See additional information for Ezogabine.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Geriatric Dose for:
Additional dosage information:
Usual Adult Dose for Epilepsy
Initial dose: 100 mg orally 3 times daily. The dose may be increased by a maximum of 50 mg 3 times daily (150 mg per week) based on clinical response.
Maintenance dose: 200 to 400 mg orally 3 times daily (600 to 1,200 mg orally daily)
Maximum dose: 400 mg orally 3 times daily (1,200 mg orally daily)
Usual Geriatric Dose for Epilepsy
Initial dose: 50 mg orally 3 times daily. The dose may be increased by a maximum of 50 mg 3 times daily (150 mg per week) based on clinical response.
Maximum dose: 250 mg orally 3 times daily (750 mg orally daily)
Renal Dose Adjustments
CrCl 50 to 80 mL/min: No dose adjustment recommended
CrCl less than 50 mL/min or end-stage renal disease on dialysis:
Initial dose: 50 mg orally 3 times daily. The dose may be increased by a maximum of 50 mg 3 times daily (150 mg per week) based on clinical response.
Maximum dose: 200 mg orally 3 times daily (600 mg orally daily)
Liver Dose Adjustments
Child-Pugh score 5 to 6: No adjustment recommended
Child-Pugh score 7 to 9:
Initial dose: 50 mg orally 3 times daily. The dose may be increased by a maximum of 50 mg 3 times daily (150 mg per week) based on clinical response.
Maximum dose: 250 mg orally 3 times daily (750 mg orally daily)
Child-Pugh score greater than 9:
Initial dose: 50 mg orally 3 times daily. The dose may be increased by a maximum of 50 mg 3 times daily (150 mg per week) based on clinical response.
Maximum dose: 200 mg orally 3 times daily (600 mg orally daily)
Dose Adjustments
Ezogabine should be titrated according to clinical response in order to achieve therapeutic efficacy and minimize adverse effects.
When discontinuing ezogabine, the dose should be reduced gradually, if possible.
Precautions
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
Other Comments
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for ezogabine. This includes a communication plan. Additional information is available at www.fda.gov/Drugs/DrugSafety/postmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.
Ezogabine may be administered with or without food.
Ezogabine should be swallowed whole and not crushed, chewed, or divided.
